Astrazeneca Stock News

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced LYNPARZA® (olaparib) has been approved in the US for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. The approval by the US Food and Drug Administration (FDA) was based on results from the OlympiA Phase III trial presented

The U.S. FDA has granted an additional indication for AstraZeneca (AZN) and Merck''s (MRK) Lynparza (olaparib) as an adjuvant treatment for a type of early-stage breast cancer.

it would serve as an annual reminder to the world of women’s socio-economic and political importance. She would never have imagined that this commemoratory day would blossom into such a critical yearly feature. A day when women across the globe are indeed celebrated, their voices heard, and their challenges discussed on meaningful platforms. The reason is simple, the women in Clara’s lifetime lived in an entirely different clime, and their struggles, in most cases, were essentially different from those of today. While several studies have shown that gender parity may not be attainable, as the World Economic Forum opined, for the next century. Yet it is no gainsaying that women had come a long way from when Clara Zetkin came up with the audacious idea of celebrating International Women’s Day (IWD). From struggling to gain access to education and being denied voting rights, women have come to lead industries, create innovative solutions to human needs, and even rule nations! And they continue to smash the glass ceiling further.

DUBLIN--(BUSINESS WIRE)--The "Research Report on China''s Anastrozole Market, 2021-2025" report has been added to ResearchAndMarkets.com''s offering. Anastrozole was developed by AstraZeneca with Arimidex as its trade name. And it was first marketed in the United States in 1995, approved by the FDA of U.S. for the treatment of advanced breast cancer in postmenopausal women. 1999 saw the introduction of AstraZeneca''s anastrozole into China, where it was approved for use in the adjuvant treatment o

Some cheap stocks are worth investing in.

Some cheap stocks are worth investing in.

Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.

Astellas Worth A Look On Revenue Re-Acceleration Potential

In a story published March 4, 2022 about federal COVID-19 funding, The Associated Press erroneously described AstraZeneca’s COVID-19 prophylactic for immunocompromised individuals as a pill, when in fact it is delivered by injection

Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.

Hutchmed (​HCM) said it received a $15M milestone payment from AstraZeneca (AZN) for beginning start-up activities for a phase 3 trial of Orpathys (savolitinib) for lung cancer.The…

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“ AstraZeneca ”) (LSE/STO/Nasdaq:​AZN).

Can these health care stocks climb this month?